A phase II trial of dociparstat sodium (CX-01) in patients with myelodysplastic syndrome
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
Price : $35 *
At a glance
- Drugs Dociparstat sodium (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 19 Apr 2017 Status changed from planning to recruiting, according to a Cantex Pharmaceuticals media release.
- 11 Apr 2017 New trial record
- 04 Apr 2017 This trial is expected to begin in 2017, according to a Cantex Pharmaceuticals media release.